NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Anika Therapeutics Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.
Anika Therapeutics develops hyaluronic acid-based products for orthopedic pain management and regenerative solutions. Its portfolio includes viscosupplements for osteoarthritis pain relief, tissue repair scaffolds, and injectable bone substitutes, along with non-orthopedic products for veterinary, surgical, and ophthalmic applications. The company sells through partnerships with healthcare distributors and directly to clinicians in hospitals, surgical centers, and office-based settings globally.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Anika Therapeutics Inc stock.
Slightly overvalued: intrinsic value $11.28 per share, market price $12.85, margin of safety -13.9% (as of 2026-11-17).
Its through-the-cycle earnings (11.9% median margin), capitalised at 7.1% with no growth, values the shares at $11.28; the price of $12.85 is 14% above that value.
17 more funds hold it; the full list is part of the paid plan.
All 82 Drug Manufacturers - Specialty & Generic stocks
11 more in this industry show a wider margin of safety.
ANIK is slightly overvalued (as of the 2026-11-17 close). Its through-the-cycle earnings (11.9% median margin), capitalised at 7.1% with no growth, values the shares at $11.28; the price of $12.85 is 14% above that value.
$11.28 per share (as of the 2026-11-17 close), against a market price of $12.85. That is a margin of safety of -13.9%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.